CREATE Health - a Translational Cancer Centre
| Reference number | |
| Coordinator | Lunds universitet - CREATE Health |
| Funding from Vinnova | SEK 9 000 000 |
| Project duration | January 2012 - June 2015 |
| Status | Completed |
Purpose and goal
The projects have worked well and the goals were reached. Start-up companies have taken over parts of the projects at appropriate phase in the projects. There is great potential for commercialization for several of the projects and for the majority of the projects solutions have been decided or discussed. The large number of publications as a result of the program shows on spreading of the results, which is an important factor in order for research to progress and be valuable.
Expected results and effects
Several of the reported results potentially have commercial importance. A patent has been filed for a new biomarker for use in treatment in kidney cancer. Based on the results from this program, Cantargia AB has developed a humanized antibody for clinical phase I/II studies.. Immunovia AB was granted 43 million Swedish kronor for developing molecular tools for early diagnosis of pancreatic cancer. This proofs practical implementation of results from CREATE Health within a short space of time.
Planned approach and implementation
The layout of the project with several subprojects has worked very well, and this is also clear from the results and the large number of publications produced. The coordinator has in a successful manner organized the projects and the PIs, and we have had regular coordination meetings.